NIMBLE

Non-inferiority study of GSK3511294 compared with mepolizumab or benralizumab in participants with severe asthma with an eosinophilic phenotype.

Adults and adolescents ≥ 12 years) at the time of signing the informed consent.

Documented physician diagnosis of asthma for ≥ 2 years

Anti-Il-5/5R Therapy: Receiving either mepolizumab 100mg SC or benralizumab 30mg SC for ≥12 months prior to Screening and have a documented benefit to therapy asses by either:

• Reduction in exacerbation frequency since initiating treatment
• Reduction in maintenance OCS since initiating treatment

A well document requirement for regular treatment with medium to high dose ICS in the 12 months prior to Visit 1 with or without maintenance OCS.

Additional Controller Medication: Current treatment with at least one additional controller medication, besides ICS.

Female Participants: A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:

• Is a woman of non-childbearing potential
• Is a woman of childbearing potential and using a contraceptive method that is highly effective, with a failure rate of <1% from at least 14 days prior to the first dose of study intervention until at least 30 weeks after either the first dose or the dose at Week 26